A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE001 (USA) · Dr. Reyes
consented 2023-01-17
AEs
3
Serious
0
Dropout signal
–
Adverse events
mild
assessed
Grade 1 Decreased appetite — outcome: RECOVERED/RESOLVED; onset 2023-04-21 (study day 81); relationship: not assessed
severe
assessed
Grade 3 Anaemia — outcome: RECOVERED/RESOLVED; onset 2023-05-15 (study day 105); relationship: not assessed
moderate
assessed
Grade 2 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-07-25 (study day 176); relationship: N
Data queries
No data queries.